The variation over time of the cardiac biomarker cMyC
Research type
Research Study
Full title
Measurement of week-to-week biological variation of cardiac myosin-binding protein C (cMyC)
IRAS ID
241895
Contact name
Michael Marber
Contact email
Duration of Study in the UK
0 years, 6 months, 31 days
Research summary
Cardiac myosin-binding protein C (cMyC) is a cardiac specific protein that is released rapidly after acute myocardial injury. cMyC may be used for early diagnosis of acute coronary syndromes and as a prognostic biomarker.
The reference change value (RCV) is defined as the minimal difference needed between two consecutive laboratory results to be certain (with a specified level of confidence) that the results are truly different, and that the difference is not due simply to analytical imprecision (CV A ) and intra-individual biological variation (CV I ). Knowledge of the RCV for a biomarker is important when the results of serial blood samplings are interpreted, as is done in the investigation of acute coronary syndromes, and when the performance of a biomarker as prognostic marker is evaluated since markers with large within individual biological variation may perform less well as risk estimators for individual subjects.
These criteria are used as quality goals by laboratories and external quality assessment schemes who continuously evaluate the analytical quality of biomarkers.
The study will be performed according to the latest EFLM checklist for biological variation studies.REC name
South Central - Berkshire Research Ethics Committee
REC reference
18/SC/0310
Date of REC Opinion
30 May 2018
REC opinion
Favourable Opinion